iTeos Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
iTeos Therapeutics, Inc. carries a market capitalization of 448.68M, placing it among publicly traded companies globally. Its enterprise value stands at -78.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 448.68M |
| Enterprise Value | -78.46M |
Share Statistics
iTeos Therapeutics, Inc. currently has 44.17M shares outstanding.
| Shares Outstanding | 44.17M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -3.51 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | -4.02 |
| P/OCF Ratio | -4.00 |
Financial Position
iTeos Therapeutics, Inc. maintains a current ratio of 7.53, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.53 |
| Quick Ratio | 7.37 |
| Debt / Equity | 1.04 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -128.18 |
| Return on Assets (ROA) | -29.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 12.37M |
| Effective Tax Rate | N/A |
Stock Price Statistics
iTeos Therapeutics, Inc.'s stock has declined approximately -0.58765916% over the past 52 weeks. The 50-day moving average sits at 10.13, while the 200-day moving average is 8.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -0.58765916% |
| 50-Day Moving Average | 10.13 |
| 200-Day Moving Average | 8.29 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -200.45M, while operating income came in at -201.74M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -201.74M |
| Pretax Income | -190.04M |
| Net Income | -202.41M |
| EBITDA | -200.45M |
| EBIT | -201.74M |
| Earnings Per Share (EPS) | -4.67 |
Balance Sheet
iTeos Therapeutics, Inc. holds 515.43M in cash and equivalents against 5.13M in total debt, resulting in a net debt position of -207.82M. Total book value stands at -123.08M, with working capital of 458.72M providing operational flexibility.
| Cash & Cash Equivalents | 515.43M |
| Total Debt | 5.13M |
| Net Debt | -207.82M |
| Equity (Book Value) | -123.08M |
| Book Value Per Share | -2.84 |
| Working Capital | 458.72M |
Cash Flow
iTeos Therapeutics, Inc. produced -108.06M in operating cash flow over the past twelve months. After subtracting -630,000.00 in capital expenditures, free cash flow totaled -108.69M - equivalent to -2.51 per share.
| Operating Cash Flow | -108.06M |
| Capital Expenditures | -630,000.00 |
| Free Cash Flow | -108.69M |
| FCF Per Share | -2.51 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.01 |
| FCF Yield | -24.88 |
Scores
iTeos Therapeutics, Inc. posts an Altman Z-Score of 1.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.54 |